Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly & Co. Global External R&D-Asia VP Tony Zhang on Lilly's FIPNET Strategies In China: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Eli Lilly, which launched its GLP-1 agonist Byetta (exenatide) in China in 2009, recently expanded its fully integrated pharmaceutical network (FIPNET) strategy by announcing that it would build up a diabetes-focused research center in Shanghai. Following the announcement, Tony Zhang, PhD, Lilly's global external R&D-Asia VP, sat down with PharmAsia News' Shanghai bureau along the sidelines of the BioPartnering China conference to talk about Lilly's evolving R&D strategy in Asia.

You may also be interested in...



Pfizer Sees Deeper Price Cuts, Lilly Maintains China Momentum – Emerging Market Earnings Roundup (Part 2)

Pfizer said that it has plans to rebound from a volatile fourth quarter of price cuts and slower than expected volume gains in emerging markets. Eli Lilly hopes to build on gains in China and boost volume growth overall in emerging markets to shore up revenues after major patents expired in key countries.

Emerging Markets Round Up From JP Morgan Healthcare Conference (Part 1 of 2)

Emerging markets took center stage among Big Pharma presentations at the annual JP Morgan Healthcare Conference in San Francisco last week.

Emerging Markets Round Up From JP Morgan Healthcare Conference (Part 1 of 2)

Emerging markets took center stage among Big Pharma presentations at the annual JP Morgan Healthcare Conference in San Francisco last week.

Related Content

UsernamePublicRestriction

Register

OM000882

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel